Abdominal Aortic Aneurysm during the Pandemic: Should They Be Operated or Deferred?

Some European societies have recommended deferring the treatment of infrarenal abdominal aortic aneurysm (AAA) ≥5.5 cm during the COVID-19 pandemic. However, these documents have also suggested optimal deferral times, and everything must be adjusted according to the transmission risk/risk of rupture balance.

Intervenir o diferir aneurismas de aorta abdominal en pandemia

Annual risk of rupture can be estimated based on a prospective cohort published by McGuinness et al. Almost 200 patients had regrets about their elective treatment and, after 5 years of follow-up, had rupture rates of 9.5%, 10.2%, and 32.5% for aneurysms of 5.5-5.9 cm, 6-6.9 cm, and ≥7 cm, respectively.

We could assume that perioperative COVID-19-related mortality and community risk are equivalent.

This model calculates the “optimal strategy” (repair or deferral) at different timepoints (3, 6, 9, and 12 months) based on baseline characteristics, risk of rupture, surgical risk, and COVID-19-related mortality risk.

The COVID-19 infection risk was stratified by community virus prevalence and nosocomial transmission (estimated as at least twice the community transmission risk).

Results suggest any aneurysm could be deferred for 3 months.


Read also: La durabilidad del TAVI pasa a un segundo plano con los resultados del TRANSIT.


Surgical repair can be deferred up to 6 months only in young patients (<65 years old) with aneurysms >7cm when the risk of COVID-19 transmission is low.

Endovascular repair (non-open) can be deferred 3 months—or even 6 months—in most scenarios, based on the risk of COVID-19 transmission.

These recommendations support deferral for most patients, but also warn that not everyone will conform to this, and decisions must be made on a case-by-case basis.

PIIS1078588421004524free

Original Title: COVID-19 and abdominal aortic aneurysm intervention: when to defer and when to operate.

Reference: Brenig L. Gwilym et al. European Journal of Vascular & Endovascular Surgery 2021. Journal Pre-proof. https://doi.org/10.1016/j.ejvs.2021.05.034.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....